HOME >> BIOLOGY >> NEWS
Enzymes Targeted As Key To Understanding Drug Interactions

You go to one doctor for your back problem. You see another for high blood pressure. Perhaps you consult a third for a nagging sinus infection. As part of your treatment, each writes a prescription or two. The result can be an array of pill bottles on your bathroom counter or breakfast table, perhaps augmenting your usual arsenal of over-the-counter supplements and pain and cold remedies.

How is the patient -- or the health care professional -- to know when the potential exists for a serious, even life-threatening, interaction between medications? Or when one drug may render another ineffective? News stories have highlighted the problem of pharmacists who failed to question prescriptions for dangerous drug combinations, and pharmacists complain of computer programs that fail to give them adequate warning of possible interactions.

A notorious example of a potentially deadly drug duo was Seldane, a popular antihistamine, and erithromycin, a common antibiotic, which when taken together could produce sometimes fatal heart problems. The U.S. Food and Drug Administration (FDA) has recommended that Seldane be withdrawn from the market.

Prevention of drug interactions, say researchers at the University of Washington School of Pharmacy, lies in learning how the human body processes each drug.

The school has recently established a formal Program in Drug Interactions, tapping the expertise of 22 faculty members believed to be the largest group of experts in the world on drug interactions.

The UW investigators are seeking systematic knowledge of how various enzymes -- biochemical catalysts produced by the body -- metabolize drugs. Their research is producing an understanding of the potential for adverse effects among thousands of drug combinations.

"Pharmacists have had to remember hundreds of pairs of drugs that interact," said the program's director, Dr. Rene Levy, professor and chair of pharmaceutics. "But there was a shift in our knowedge
'"/>

Contact: Laurie McHale
lmchale@u.washington.edu
206-543-3620
University of Washington
28-May-1997


Page: 1 2

Related biology news :

1. Constructing "Designer" Plant Enzymes
2. Engineering New Enzymes
3. Spinach Enzymes Neutralize Explosives
4. Worm Wizardry: Worlds Most Heat-Tolerant Creature Suggests Enzymes For Drugs OrIndustry, UD Prof Says
5. Targeted therapy knocks out pediatric brain cancer in mice
6. Targeted therapy for lung cancer patients shows promise in extending lives
7. Targeted immunotherapy eradicates cancer in mice
8. Targeted radiation to liver tumors spares tissue, improves quality of life
9. Targeted Genetics presents data on arthritis gene therapy
10. Targeted genetics presents promising data from cystic fibrosis clinical trial
11. Targeted Genetics presents clinical data on E1A cancer gene therapy

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Enzymes Targeted Key Understanding Drug Interactions

(Date:5/22/2015)... 2015 According to a new ... 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), by Hardware ... Consumer and Home) - Global Forecast to 2020", published ... Billion in 2015 to $6.19 Billion by 2020, at ... market data Tables and   43 Figures spread through ...
(Date:5/21/2015)... The Sync Project™ , a global ... today announced a collaborative partnership with Berklee,s Institute ... on collaboration on original research, joint course development and ... collaboration, The Sync Project and BerkleeICE are exploring the ... the 2015-2016 academic year.  The course ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... at The Jefferies 2015 Global Healthcare Conference in ... , 2015 at 8:30am Eastern time.  ... webcast at: http://wsw.com/webcast/jeff88/hae ... a global healthcare company dedicated to providing innovative blood ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 Optivia ... assay services for Drug-Drug Interactions (DDI), Metabolism and ... a world leader in assessing impact of drugs ... Pharmacology supported by biosimulation, announced today that they ... allows both companies to expand their product and ...
Breaking Biology Technology:Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
Cached News: